stockrow
Saturday 7 November 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00.
- EPS
- −17.9%
- Free cash flow
- −3.25%
- Total debt
- −52.9%
Quarter to June 2026, against a year earlier
4.40
0.29
+7.06%
Follow EXOZ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | — | — | — | — | 1 | 1 | 5 | +198.1% | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | (2) | (6) | (9) | (10) | +115.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (2,847.50) | 0.00 | 0.00 | 0.00 | +2,847.5 pt | ||||||
| Net income | — | — | — | — | — | — | — | (2) | (6) | (9) | (10) | +112.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (0.33) | (0.89) | (1.09) | (1.19) | +82.8% | ||||||
| Cash flow | — | — | — | — | — | — | — | (0.19) | (1.30) | (0.78) | (0.81) | +102.7% | ||||||
| Capex | — | — | — | — | — | — | — | (0.05) | (0.06) | (0.02) | (0.02) | (33.7%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (0.24) | (1.36) | (0.80) | (0.82) | +84.0% | ||||||
| Book value | — | — | — | — | — | — | — | (0.06) | 1.59 | 0.41 | 0.42 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 6 | 7 | 8 | 8 | +15.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | — | — | 10.43 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | (14.77) | — | — | (5.03) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (9) | (7) | (7) | +134.6% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | (23.3%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (9) | (7) | (7) | +113.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (1) | 9 | 2 | 5 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | 0 | (10) | (3) | (6) | +568.8% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 0 | 10 | 3 | 4 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (70.65) | (96.38) | (115.42) | (96.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (528.52) | (1,438.03) | 0.00 | (1,438.0) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (116.80) | (132.56) | (187.16) | (132.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 31 | 32 | — | +3.2% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023
eXoZymes Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HYPD Hyperion DeFi, Inc. | $39.8M | — (loss-making) | 0.5× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| Median of peers | $37.7M | — | — | +1,139.03% | — | +9.54% | 33.34% | 0.00% |